Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Schattenberg

Showing results (151-160 of 333) with videos related to

Pageof 34
Sort By:
European Journal of Internal Medicine|September 3, 2020
Impact of non-selective ß-blockers on hepatic encephalopathy in patients with liver cirrhosisChristian Labenz, Michael Nagel, Gerrit Toenges, et al.
Hepatology Communications|October 30, 2023
Development and evaluation of a virtual reality driving test for patients with cirrhosisSimon J Gairing, Eva M Schleicher, Leonard Kaps, et al.
Journal of Hepatology|May 1, 2020
Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver ForumOliver Glass, Claudia Filozof, Mazen Noureddin, et al.
Zeitschrift Fur Gastroenterologie|June 17, 2015
[First data concerning the medical supply of patients with non-alcoholic fatty liver disease in Germany - a survey in university hospital centers of hepatology]J Weiss, M Rau, H Bantel, et al.
Scientific Reports|September 9, 2021
Toll-like receptor 1 as a possible target in non-alcoholic fatty liver diseaseAnja Baumann, Anika Nier, Angélica Hernández-Arriaga, et al.
Scientific Reports|October 16, 2021
Elevated serum levels of methylglyoxal are associated with impaired liver function in patients with liver cirrhosisMaurice Michel, Cornelius Hess, Leonard Kaps, et al.
Journal of Hepatology|March 31, 2023
A proposal from the liver forum for the management of comorbidities in non-alcoholic steatohepatitis therapeutic trialsRaluca Pais, Bertrand Cariou, Mazen Noureddin, et al.
Gut|July 30, 2025
Thrombospondin-2 is a performant biomarker of at-risk MASH and advanced MASH fibrosis in a large multicentre European cohortVlad Ratziu, Rambabu Surabattula, Elisabetta Bugianesi, et al.
Journal of Clinical Medicine|August 12, 2022
Non-Invasive Detection of Fibrotic NASH in NAFLD Patients with Low or Intermediate FIB-4Katharina John, Martin Franck, Sherin Al Aoua, et al.
Gastroenterologia Y Hepatologia|October 27, 2023
Risk factors for fibrosis progression in non-alcoholic steatohepatitis: Analysis of the European cohort in the real-world GAIN studyAnum Shaikh, Gabriel Pedra, Leonardo Ruiz-Casas, et al.
Pageof 34

Showing results (151-160 of 333) with videos related to

Sort By:
Pageof 34
European Journal of Internal Medicine|September 3, 2020
Impact of non-selective ß-blockers on hepatic encephalopathy in patients with liver cirrhosisChristian Labenz, Michael Nagel, Gerrit Toenges, et al.
Hepatology Communications|October 30, 2023
Development and evaluation of a virtual reality driving test for patients with cirrhosisSimon J Gairing, Eva M Schleicher, Leonard Kaps, et al.
Journal of Hepatology|May 1, 2020
Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver ForumOliver Glass, Claudia Filozof, Mazen Noureddin, et al.
Zeitschrift Fur Gastroenterologie|June 17, 2015
[First data concerning the medical supply of patients with non-alcoholic fatty liver disease in Germany - a survey in university hospital centers of hepatology]J Weiss, M Rau, H Bantel, et al.
Scientific Reports|September 9, 2021
Toll-like receptor 1 as a possible target in non-alcoholic fatty liver diseaseAnja Baumann, Anika Nier, Angélica Hernández-Arriaga, et al.
Scientific Reports|October 16, 2021
Elevated serum levels of methylglyoxal are associated with impaired liver function in patients with liver cirrhosisMaurice Michel, Cornelius Hess, Leonard Kaps, et al.
Journal of Hepatology|March 31, 2023
A proposal from the liver forum for the management of comorbidities in non-alcoholic steatohepatitis therapeutic trialsRaluca Pais, Bertrand Cariou, Mazen Noureddin, et al.
Gut|July 30, 2025
Thrombospondin-2 is a performant biomarker of at-risk MASH and advanced MASH fibrosis in a large multicentre European cohortVlad Ratziu, Rambabu Surabattula, Elisabetta Bugianesi, et al.
Journal of Clinical Medicine|August 12, 2022
Non-Invasive Detection of Fibrotic NASH in NAFLD Patients with Low or Intermediate FIB-4Katharina John, Martin Franck, Sherin Al Aoua, et al.
Gastroenterologia Y Hepatologia|October 27, 2023
Risk factors for fibrosis progression in non-alcoholic steatohepatitis: Analysis of the European cohort in the real-world GAIN studyAnum Shaikh, Gabriel Pedra, Leonardo Ruiz-Casas, et al.
Pageof 34